Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 13, 2022
Treatment Sequencing in Resectable Lung Cancer: The Good and the Bad of Adjuvant Versus Neoadjuvant TherapyMariano Provencio, Virginia Calvo, Atocha Romero, et al.
Biomedicines|April 3, 2021
The Role of Metabolism in Tumor Immune Evasion: Novel Approaches to Improve ImmunotherapyAlberto Cruz-Bermúdez, Raquel Laza-Briviesca, Marta Casarrubios, et al.
Biochimie|January 29, 2013
Evaluation of mitochondrial function and metabolic reprogramming during tumor progression in a cell model of skin carcinogenesisCarmen G Vallejo, Alberto Cruz-Bermúdez, Paula Clemente, et al.
Oncotarget|April 25, 2015
Enhanced tumorigenicity by mitochondrial DNA mild mutationsAlberto Cruz-Bermúdez, Carmen G Vallejo, Ramiro J Vicente-Blanco, et al.
Oncotarget|March 28, 2020
Correction: Enhanced tumorigenicity by mitochondrial DNA mild mutationsAlberto Cruz-Bermúdez, Carmen G Vallejo, Ramiro J Vicente-Blanco, et al.
Scientific Reports|December 2, 2017
PGC-1alpha levels correlate with survival in patients with stage III NSCLC and may define a new biomarker to metabolism-targeted therapyAlberto Cruz-Bermúdez, Ramiro J Vicente-Blanco, Raquel Laza-Briviesca, et al.
Plos One|January 20, 2016
Functional Characterization of Three Concomitant MtDNA LHON Mutations Shows No Synergistic Effect on Mitochondrial ActivityAlberto Cruz-Bermúdez, Ramiro J Vicente-Blanco, Rosana Hernández-Sierra, et al.
Clinical Chemistry and Laboratory Medicine|August 31, 2019
Next-generation sequencing for tumor mutation quantification using liquid biopsiesMariano Provencio, Clara Pérez-Barrios, Miguel Barquin, et al.
Oncotarget|September 27, 2017
Dynamic circulating tumor DNA quantificaton for the individualization of non-small-cell lung cancer patients treatmentMariano Provencio, María Torrente, Virgina Calvo, et al.
Oncotarget|September 24, 2017
Concordance between circulating tumor cells and clinical status during follow-up in anaplastic lymphoma kinase (ALK) non-small-cell lung cancer patientsMariano Provencio, David Pérez-Callejo, María Torrente, et al.
Pageof 4